Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Solvonis Therapeutics ( (GB:SVNS) ) has issued an update.
Solvonis Therapeutics has appointed Paul Carter as a Non-Executive Director to support its strategic growth. Carter’s extensive experience in the biopharmaceutical industry is expected to enhance Solvonis’ efforts in advancing its CNS pipeline and executing a capital-efficient, licensing-first growth strategy. This appointment is anticipated to strengthen the company’s board and contribute to its sustainable growth, benefiting both patients and shareholders.
More about Solvonis Therapeutics
Solvonis Therapeutics plc is an emerging biopharmaceutical company focused on developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Based in London and listed on the London Stock Exchange, the company is advancing a pipeline of repurposed and novel compounds targeting addiction, psychiatry, and neurology. Solvonis’ lead programs include treatments for Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with ongoing efforts to expand into broader CNS indications.
Average Trading Volume: 67,121,519
Technical Sentiment Signal: Buy
Current Market Cap: £23.06M
For detailed information about SVNS stock, go to TipRanks’ Stock Analysis page.